ECSP088682A - Modulación de la formación ósea - Google Patents

Modulación de la formación ósea

Info

Publication number
ECSP088682A
ECSP088682A EC2008008682A ECSP088682A ECSP088682A EC SP088682 A ECSP088682 A EC SP088682A EC 2008008682 A EC2008008682 A EC 2008008682A EC SP088682 A ECSP088682 A EC SP088682A EC SP088682 A ECSP088682 A EC SP088682A
Authority
EC
Ecuador
Prior art keywords
ror2
bone
relates
bone formulation
modulation
Prior art date
Application number
EC2008008682A
Other languages
English (en)
Inventor
Julia Billiard
Yan Liu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP088682A publication Critical patent/ECSP088682A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Esta invención se refiere a modular la actividad Ror (por ejemplo, la actividad de la proteína Ror2) o 14-3-3 b para afectar la formación o la resorción ósea. La invención se relaciona además con composiciones y métodos para la selección, diagnóstico y desarrollo de terapias para trastornos relacionados con huesos tal como osteoporosis y fracturas de hueso. Los anticuerpos y fragmentos de anticuerpo dirigidos a la proteína Ror2 son particularmente útiles para originar la dimerización de las proteínas Ror2, conduciendo de esta manera la activación del Ror2.
EC2008008682A 2006-02-17 2008-08-15 Modulación de la formación ósea ECSP088682A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77453406P 2006-02-17 2006-02-17
US84423906P 2006-09-13 2006-09-13

Publications (1)

Publication Number Publication Date
ECSP088682A true ECSP088682A (es) 2008-09-29

Family

ID=38437973

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008682A ECSP088682A (es) 2006-02-17 2008-08-15 Modulación de la formación ósea

Country Status (19)

Country Link
US (1) US20090047287A1 (es)
EP (1) EP1984395A2 (es)
JP (1) JP2009527485A (es)
KR (1) KR20080095269A (es)
AR (1) AR060104A1 (es)
AU (1) AU2007217779A1 (es)
BR (1) BRPI0707864A2 (es)
CA (1) CA2638803A1 (es)
CR (1) CR10212A (es)
EC (1) ECSP088682A (es)
IL (1) IL193271A0 (es)
MX (1) MX2008010511A (es)
NO (1) NO20083497L (es)
PA (1) PA8715601A1 (es)
PE (1) PE20071309A1 (es)
RU (1) RU2008131052A (es)
SV (1) SV2009002997A (es)
TW (1) TW200800266A (es)
WO (1) WO2007098198A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011138414A1 (en) * 2010-05-05 2011-11-10 Addex Pharma Sa Methods and tools for screening agents exhibiting an activity on receptors of the tumor necrosis factor receptor superfamily
WO2013070033A1 (ko) * 2011-11-09 2013-05-16 주식회사 아이엠헬스케어 골다공증 및 골회전율 진단 스트립
KR101354826B1 (ko) * 2011-12-08 2014-01-27 아주대학교산학협력단 중간엽줄기세포 렙틴분비능을 이용한 골다공증 예방 또는 치료용 물질 스크리닝 방법
US20140322234A1 (en) * 2012-01-03 2014-10-30 The Board Of Trustees Of The Leland Stanford Junior University Analysis and Targeting of ROR2 in Cancer
JP6463029B2 (ja) * 2013-08-02 2019-01-30 有未 伊谷 ヒト間葉系幹細胞を特異的に認識するモノクローナル抗体並びにこれを用いたヒト間葉系幹細胞の分離及び/または品質評価を行う方法
AU2015297347B2 (en) * 2014-08-01 2021-05-27 PuREC Co., Ltd Method for evaluating quality of human mesenchymal stem cell, and monoclonal antibody for use in said method
JP7057557B2 (ja) * 2015-07-31 2022-04-20 国立大学法人大阪大学 上皮疾患に対する治療及び/又は予防有効性を評価する方法、上皮疾患治療剤のスクリーニング方法、及び上皮疾患治療剤
EP4122958A1 (en) 2016-05-13 2023-01-25 BioAtla, Inc. Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
GB201718985D0 (en) 2017-11-16 2018-01-03 Univ London Queen Mary Treatment
US11793452B2 (en) 2019-10-03 2023-10-24 Johnson & Johnson Consumer Inc. Method of visualizing and quantifying remineralization
CN115786252B (zh) * 2023-02-07 2023-05-05 赛德特生物制药有限公司 人脐带间充质干细胞成骨诱导分化培养基及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312814A (en) * 1992-12-09 1994-05-17 Bristol-Myers Squibb Co. α-phosphonocarboxylate squalene synthetase inhibitors
WO2001068812A2 (en) * 2000-03-14 2001-09-20 Regeneron Pharmaceuticals, Inc. Methods of stimulating cartilage formation
WO2004073731A1 (en) * 2003-02-19 2004-09-02 Aziz Ghahary 14-3-3 protein for prevention and treatment of fibroproliferative disorders
WO2004094641A2 (en) * 2003-04-16 2004-11-04 Wyeth A novel method of modulating bone-realted activity

Also Published As

Publication number Publication date
MX2008010511A (es) 2008-11-18
EP1984395A2 (en) 2008-10-29
JP2009527485A (ja) 2009-07-30
SV2009002997A (es) 2009-04-17
US20090047287A1 (en) 2009-02-19
WO2007098198A2 (en) 2007-08-30
BRPI0707864A2 (pt) 2011-05-10
TW200800266A (en) 2008-01-01
CA2638803A1 (en) 2007-08-30
CR10212A (es) 2008-10-03
NO20083497L (no) 2008-10-31
KR20080095269A (ko) 2008-10-28
PE20071309A1 (es) 2008-02-13
PA8715601A1 (es) 2008-11-19
IL193271A0 (en) 2011-08-01
RU2008131052A (ru) 2010-03-27
WO2007098198A3 (en) 2008-03-13
AR060104A1 (es) 2008-05-28
AU2007217779A1 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
CR10212A (es) Modulacion de la formacion osea
CY1119127T1 (el) Επιτοποι σκληροστινης
EA200600038A1 (ru) Антитела, специфические в отношении склеростина, и способы увеличения минерализации кости
CY1115588T1 (el) Αναστολεις ανθρωπινης πρωτεϊνικης φωσφατασης τυροσινης-β και η φαρμακευτικη χρηση τους
CY1114872T1 (el) Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης
CY1116377T1 (el) Αναστολεις της ανθρωπινης πρωτεϊνικης φωσφατασης της τυροσινης και μεθοδοι χρησης
BR0315275A (pt) Anticorpos que se ligam a receptor de eritropoietina
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
DE602004030354D1 (de) Systeme mit wechselbaren hörnern zur herstellung von eingeschlossenen produkten
CY1112797T1 (el) Συμπλοκο σκληροστινης και νογκινης ή χορδινης, και παραγοντες που ρυθμιζουν το σχηματισμο του εν λογω συμπλοκου
TW200638934A (en) Heteroaryl compounds as P2Y1 receptor inhibitors
MX2009007688A (es) Gel de fibrina para liberacion controlada de tgp-beta y usos del mismo.
ATE403149T1 (de) Diagnostische tests auf periostinbasis
WO2018115017A3 (en) CRYSTALLINE STRUCTURE OF GREMLIN-1 AND ANTIBODY INHIBITOR
ATE423565T1 (de) Verwendung von substanz p zur mobilisierung und proliferation mesenchymaler stammzellen und zur wundheilung
WO2011116212A3 (en) Bone morphogenetic protein receptor binding agents and methods of their use
DE602005003830D1 (de) Vorrichtung zur befestigung von knochenlappen nach einer kraniotomie
GB0324656D0 (en) A protein involved in ovarian cancer
ATE357255T1 (de) Plazenta-wachstumsfaktor als target für die behandlung von osteoporose
EP3996614C0 (de) Frakturfixationsplatte zur applikation am proximalen humerus
DE502004010446D1 (de) Osteosyntheseplatte zur operativen versorgung von knochenfrakturen
ATE417035T1 (de) Vitamin-d3-analoga zur prävention undbehandlung von knochenerkrankungen
HK40073521A (en) Human antibodies to bone morphogenetic protein 6
BR0316995A (pt) Modulação anti-sentido da expressão de mitoneet
UY27815A1 (es) Agonistas de prostaglandinas utiles en el tratamiento de desordenes oseos